ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β (2021)
Vinh, Donald C. ; Abel, Laurent ; Bastard, Paul ; Cheng, Matthew P. ; Condino Neto, Antonio ; Gregersen, Peter K. ; Haerynck, Filomeen ; Cicalese, Maria-Pia ; Hagin, David; Palacín, Pere Soler ; Planas, Anna M. ; Pujol, Aurora ; Notarangelo, Luigi D. ; Zhang, Qian ; Su, Helen C. ; Casanova, Jean-Laurent ; Meyts, Isabelle
Source: Journal of Clinical Immunology. Unidade: ICB
Subjects: IMUNOLOGIA, IMUNIDADE, IMUNODEFICIÊNCIA DE VARIÁVEL COMUM, IMUNOGENÉTICA, COVID-19, INTERFERON TIPO I, INFECÇÕES POR CORONAVIRUS, ESTUDOS DE COORTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VINH, Donald C. et al. Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. Journal of Clinical Immunology. New York: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1007/s10875-021-01068-6. Acesso em: 16 nov. 2024. , 2021
APA
Vinh, D. C., Abel, L., Bastard, P., Cheng, M. P., Condino Neto, A., Gregersen, P. K., et al. (2021). Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. Journal of Clinical Immunology. New York: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1007/s10875-021-01068-6
NLM
Vinh DC, Abel L, Bastard P, Cheng MP, Condino Neto A, Gregersen PK, Haerynck F, Cicalese M-P, Hagin D, Palacín PS, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova J-L, Meyts I. Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β [Internet]. Journal of Clinical Immunology. 2021 ; 1-18.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s10875-021-01068-6
Vancouver
Vinh DC, Abel L, Bastard P, Cheng MP, Condino Neto A, Gregersen PK, Haerynck F, Cicalese M-P, Hagin D, Palacín PS, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova J-L, Meyts I. Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β [Internet]. Journal of Clinical Immunology. 2021 ; 1-18.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s10875-021-01068-6
Artigo de periodico
Hemopressin as a breakthrough for the cannabinoid field (2021)
Heimann, Andrea S. ; Dale, Camila Squarzoni ; Guimarães, Francisco Silveira ; Reis, Ricardo A. M. ; Navon, Ami ; Shmuelov, Michal A.; Rioli, Vanessa; Gomes, Ivone; Devi, Lakshmi L.; Ferro, Emer Suavinho
Source: Neuropharmacology. Unidades: ICB, FMRP
Subjects: ANATOMIA, FARMACOLOGIA, CANABINOIDES, RECEPTORES, PEPTÍDEOS, HEMOGLOBINAS, CAMUNDONGOS, MITOCÔNDRIAS, ANTI-INFLAMATÓRIOS, MATERIAIS NANOESTRUTURADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEIMANN, Andrea S. et al. Hemopressin as a breakthrough for the cannabinoid field. Neuropharmacology, v. 183, p. 12 , 2021Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2020.108406. Acesso em: 16 nov. 2024.
APA
Heimann, A. S., Dale, C. S., Guimarães, F. S., Reis, R. A. M., Navon, A., Shmuelov, M. A., et al. (2021). Hemopressin as a breakthrough for the cannabinoid field. Neuropharmacology, 183, 12 . doi:10.1016/j.neuropharm.2020.108406
NLM
Heimann AS, Dale CS, Guimarães FS, Reis RAM, Navon A, Shmuelov MA, Rioli V, Gomes I, Devi LL, Ferro ES. Hemopressin as a breakthrough for the cannabinoid field [Internet]. Neuropharmacology. 2021 ; 183 12 .[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.neuropharm.2020.108406
Vancouver
Heimann AS, Dale CS, Guimarães FS, Reis RAM, Navon A, Shmuelov MA, Rioli V, Gomes I, Devi LL, Ferro ES. Hemopressin as a breakthrough for the cannabinoid field [Internet]. Neuropharmacology. 2021 ; 183 12 .[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.neuropharm.2020.108406
Artigo de periodico
Peptidomic profiling of cerebrospinal fluid from patients with intracranial saccular aneurysms (2021)
Sakaya, Gabriel R. ; Parada, Carolina Angélica da Silva ; Eichler, Rosangela Aparecida dos Santos ; Yamaki, Vitor N. ; Navon, Ami ; Heimann, Andrea S.; Figueiredo, Eberval Gadelha ; Ferro, Emer Suavinho
Source: Journal of Proteomics. Unidades: ICB, FM
Subjects: FARMACOLOGIA, BIOMARCADORES, PEPTÍDEOS, LÍQUIDO CEFALORRAQUIDIANO, ANEURISMA INTRACRANIANO, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAKAYA, Gabriel R. et al. Peptidomic profiling of cerebrospinal fluid from patients with intracranial saccular aneurysms. Journal of Proteomics, v. 240, p. 1-13, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.jprot.2021.104188. Acesso em: 16 nov. 2024.
APA
Sakaya, G. R., Parada, C. A. da S., Eichler, R. A. dos S., Yamaki, V. N., Navon, A., Heimann, A. S., et al. (2021). Peptidomic profiling of cerebrospinal fluid from patients with intracranial saccular aneurysms. Journal of Proteomics, 240, 1-13. doi:10.1016/j.jprot.2021.104188
NLM
Sakaya GR, Parada CA da S, Eichler RA dos S, Yamaki VN, Navon A, Heimann AS, Figueiredo EG, Ferro ES. Peptidomic profiling of cerebrospinal fluid from patients with intracranial saccular aneurysms [Internet]. Journal of Proteomics. 2021 ; 240 1-13.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jprot.2021.104188
Vancouver
Sakaya GR, Parada CA da S, Eichler RA dos S, Yamaki VN, Navon A, Heimann AS, Figueiredo EG, Ferro ES. Peptidomic profiling of cerebrospinal fluid from patients with intracranial saccular aneurysms [Internet]. Journal of Proteomics. 2021 ; 240 1-13.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jprot.2021.104188
Artigo de periodico
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths (2021)
Bastard, Paul ; Gervais, Adrian ; Voyer, Tom Le ; Rosain, Jérémie ; Philippot, Quentin; Manry, Jérémy ; Michailidis, Eleftherios ; Hoffmann, Hans-Heinrich ; Eto, Shohei; Garcia-Prat, Marina; Bizien, Lucy; Parra-Martínez, Alba; Yang, Rui; Liis, Haljasmägi; Migaud, Mélanie; Särekannu, Karita; Maslovskaja, Julia; Prost, Nicolas de; Tandjaoui-Lambiotte, Yacine; Luyt , Charles-Edouard; Amador-Borrero, Blanca; Alexandre, Gaudet; Poissy, Julien; Morel, Pascal; Richard, Pascale; Cognasse, Fabrice; Troya, Jesus; Trouillet-Assant, Sophie; Belot, Alexandre; Saker, Kahina; Garçon, Pierre; Rivière, Jacques G; Lagier, Jean-Christophe; Gentile, Stéphanie; Rosen, Lindsey B; Shaw, Elana; Morio, Tomohiro; Tanaka, Junko; Dalmau, David; Tharaux, Pierre-Louis; Sene, Damien; Stepanian, Alain; Megarbane, Bruno; Triantafyllia, Vasiliki; Fekkar, Arnaud; Heath, James R; Franco, José Luis; Anaya, Juan-Manuel; Solé-Violán, Jordi; Imberti, Luisa; Biondi, Andrea; Bonfanti, Paolo; Castagnoli, Riccardo; Delmonte, Ottavia M; Zhang, Yu; Snow, Andrew L; Holland, Steven M; Biggs, Catherine M; Moncada-Vélez, Marcela; Arias, Andrés Augusto; Lorenzo, Lazaro; Boucherit, Soraya; Coulibaly, Boubacar; Anglicheau, Dany; Planas, Anna M; Haerynck, Filomeen; Duvlis, Sotirija; Nussbaum, Robert L; Ozcelik, Tayfun; Keles, Sevgi; Bousfiha, Ahmed A; ElBakkouri, Jalila; Ramirez-Santana, Carolina; Paul, Stéphane; Pan-Hammarström, Qiang; Hammarström, Lennart; Dupont, Annabelle; Kurolap, Alina; Metz, Christine N; Aiuti, Alessandro; Casari, Giorgio; Lampasona, Vito; Ciceri, Fabio; Barreiros, Lucila A; Dominguez-Garrido, Elena; Vidigal, Mateus; Zatz, Mayana ; Beek, Diederik van de; Sahanic, Sabina; Tancevski, Ivan; Stepanovskyy, Yurii; Boyarchuk, Oksana; Nukui, Yoko; Tsumura, Miyuki; Vidaur, Loreto; Tangye, Stuart G; Burrel, Sonia; Duffy, Darragh; Quintana-Murci, Lluis; Klocperk, Adam; Kann, Nelli Y; Shcherbina, Anna; Lau, Yu-Lung; Leung, Daniel; Coulongeat, Matthieu; Marlet, Julien; Koning, Rutger; Reyes, Luis Felipe; Chauvineau-Grenier, Angélique; Vene, Fabienne; Monneret, Guillaume; Nussenzweig, Michel C; Arrestier, Romain; Boudhabhay, Idris; Baris-Feldman, Hagit; Hagin, David; Wauters, Joost; Meyts, Isabelle; Dyer, Adam H; Kennelly, Sean P; Bourke, Nollaig M; Halwani, Rabih; Sharif-Askari, Narjes Saheb; Dorgham, Karim; Sallette, Jérome; Sedkaoui, Souad Mehlal; AlKhater, Suzan; Rigo-Bonnin, Raúl; Morandeira, Francisco; Roussel, Lucie; Vinh, Donald C; Ostrowski, Sisse Rye; Condino Neto, Antonio ; Prando, Carolina ; Bondarenko, Anastasiia; Spaan, András N; Gilardin, Laurent; Fellay, Jacques; Lyonnet, Stanislas; Bilguvar, Kaya; Lifton, Richard P; Mane, Shrikant; Anderson, Mark S; Boisson, Bertrand; Béziat, Vivien; Zhang, Shen-Ying; Andreakos, Evangelos; Hermine, Olivier; Pujol, Aurora; Peterson, Pärt; Mogensen, Trine; H Rowen, Lee; Mond, James; Debette, Stéphanie; Lamballerie, Xavier de; Duval, Xavier; Mentré, France; Zins, Marie; Soler-Palacin, Pere; Colobran, Roger; Gorochov, Guy; Solanich, Xavier; Susen, Sophie; Martinez-Picado, Javier; Raoult, Didier; Vasse, Marc; Gregersen, Peter K; Piemonti, Lorenzo; Rodríguez-Gallego, Carlos; Notarangelo, Luigi D; Su, Helen C; Kisand, Kai; Okada, Satoshi; Puel, Anne; Jouanguy, Emmanuelle; Rice, Charles M; Tiberghien, Pierre; Zhang, Qian; Cobat, Aurélie; Abel, Laurent; Casanova, Jean-Laurent
Source: Science Immunology. Unidades: IB, ICB
Subjects: COVID-19, INFECÇÕES POR CORONAVIRUS, ANTICORPOS, IMUNOLOGIA, HOMENS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BASTARD, Paul et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, v. 6, n. 62, p. 1-30, 2021Tradução . . Disponível em: https://doi.org/10.1126/sciimmunol.abl4340. Acesso em: 16 nov. 2024.
APA
Bastard, P., Gervais, A., Voyer, T. L., Rosain, J., Philippot, Q., Manry, J., et al. (2021). Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 6( 62), 1-30. doi:10.1126/sciimmunol.abl4340
NLM
Bastard P, Gervais A, Voyer TL, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann H-H, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Liis H, Migaud M, Särekannu K, Maslovskaja J, Prost N de, Tandjaoui-Lambiotte Y, Luyt C-E, Amador-Borrero B, Alexandre G, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier J-C, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux P-L, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya J-M, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs CM, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, ElBakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, Beek D van de, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau Y-L, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Vene F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR, Condino Neto A, Prando C, Bondarenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S, Anderson MS, Boisson B, Béziat V, Zhang S-Y, Andreakos E, Hermine O, Pujol A, Peterson P, Mogensen T, H Rowen L, Mond J, Debette S, Lamballerie X de, Duval X, Mentré F, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova J-L. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths [Internet]. Science Immunology. 2021 ; 6( 62): 1-30.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1126/sciimmunol.abl4340
Vancouver
Bastard P, Gervais A, Voyer TL, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann H-H, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Liis H, Migaud M, Särekannu K, Maslovskaja J, Prost N de, Tandjaoui-Lambiotte Y, Luyt C-E, Amador-Borrero B, Alexandre G, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier J-C, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux P-L, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya J-M, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs CM, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, ElBakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, Beek D van de, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau Y-L, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Vene F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR, Condino Neto A, Prando C, Bondarenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S, Anderson MS, Boisson B, Béziat V, Zhang S-Y, Andreakos E, Hermine O, Pujol A, Peterson P, Mogensen T, H Rowen L, Mond J, Debette S, Lamballerie X de, Duval X, Mentré F, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova J-L. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths [Internet]. Science Immunology. 2021 ; 6( 62): 1-30.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1126/sciimmunol.abl4340
Artigo de periodico
Hematologically important mutations: X-linked chronic granulomatous disease (fourth update) (2021)
Roos, Dirk; Leeuwen, Karin van; Hsu, Amy P.; Priel, Debra Long ; Begtrup, Amber ; Brandon, Rhonda; Stasia, Marie José ; Bakri, Faris Ghalib ; Köker, Nezihe ; Köker, Mustafa Yavuz ; Madkaika, Manisha; Boer, Martin de ; Morato, Maria Bravo Garcia ; Shephard, Juan Luis Valdivieso; Roesler, Joachim ; Kanegane, Hirokazu ; Kawai, Toshinao ; Matteo, Gigliola Di ; Shahrooei, Mohammad ; Bustamante, Jacinta ; Rawat, Amit ; Vignesh, Pandiarajan ; Mortaz, Esmaeil ; Fayezi, Abbas; Cagdas, Deniz ; Tezcan, Ilhan ; Kitcharoensakkul, Maleewan ; Dinauer, Mary C. ; Meyts, Isabelle; Wolach, Baruch; Condino Neto, Antonio ; Zerbe, Christa S. ; Holland, Steven M.; Malech, Harry L. ; Gallin, John I.; Kuhns, Douglas B.
Source: Blood Cells, Molecules and Diseases. Unidade: ICB
Subjects: IMUNOLOGIA, IMUNODEFICIÊNCIA DE VARIÁVEL COMUM, MUTAÇÃO GENÉTICA, DOENÇAS SANGUÍNEAS E LINFÁTICAS, SUPERÓXIDO DISMUTASE, ATIVAÇÃO ENZIMÁTICA, IMUNOGENÉTICA, ENZIMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROOS, Dirk et al. Hematologically important mutations: X-linked chronic granulomatous disease (fourth update). Blood Cells, Molecules and Diseases, v. 90, p. 1-36, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.bcmd.2021.102587. Acesso em: 16 nov. 2024.
APA
Roos, D., Leeuwen, K. van, Hsu, A. P., Priel, D. L., Begtrup, A., Brandon, R., et al. (2021). Hematologically important mutations: X-linked chronic granulomatous disease (fourth update). Blood Cells, Molecules and Diseases, 90, 1-36. doi:10.1016/j.bcmd.2021.102587
NLM
Roos D, Leeuwen K van, Hsu AP, Priel DL, Begtrup A, Brandon R, Stasia MJ, Bakri FG, Köker N, Köker MY, Madkaika M, Boer M de, Morato MBG, Shephard JLV, Roesler J, Kanegane H, Kawai T, Matteo GD, Shahrooei M, Bustamante J, Rawat A, Vignesh P, Mortaz E, Fayezi A, Cagdas D, Tezcan I, Kitcharoensakkul M, Dinauer MC, Meyts I, Wolach B, Condino Neto A, Zerbe CS, Holland SM, Malech HL, Gallin JI, Kuhns DB. Hematologically important mutations: X-linked chronic granulomatous disease (fourth update) [Internet]. Blood Cells, Molecules and Diseases. 2021 ; 90 1-36.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.bcmd.2021.102587
Vancouver
Roos D, Leeuwen K van, Hsu AP, Priel DL, Begtrup A, Brandon R, Stasia MJ, Bakri FG, Köker N, Köker MY, Madkaika M, Boer M de, Morato MBG, Shephard JLV, Roesler J, Kanegane H, Kawai T, Matteo GD, Shahrooei M, Bustamante J, Rawat A, Vignesh P, Mortaz E, Fayezi A, Cagdas D, Tezcan I, Kitcharoensakkul M, Dinauer MC, Meyts I, Wolach B, Condino Neto A, Zerbe CS, Holland SM, Malech HL, Gallin JI, Kuhns DB. Hematologically important mutations: X-linked chronic granulomatous disease (fourth update) [Internet]. Blood Cells, Molecules and Diseases. 2021 ; 90 1-36.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.bcmd.2021.102587

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects

Funding Agencies

Non normalized affiliation

Countries of institutions of collaboration